TY - JOUR T1 - Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease JF - medRxiv DO - 10.1101/2019.12.13.19014217 SP - 2019.12.13.19014217 AU - Sonia M Vallabh AU - Eric Vallabh Minikel AU - Victoria J Williams AU - Becky C Carlyle AU - Alison J McManus AU - Chase D Wennick AU - Anna Bolling AU - Bianca A Trombetta AU - David Urick AU - Chloe K Nobuhara AU - Jessica Gerber AU - Holly Duddy AU - Ingolf Lachmann AU - Christiane Stehmann AU - Steven J Collins AU - Kaj Blennow AU - Henrik Zetterberg AU - Steven E Arnold Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/15/2019.12.13.19014217.abstract N2 - BACKGROUND Fluid biomarkers are important in the development of therapeutics to delay or prevent prion disease, but have not been systematically evaluated in pre-symptomatic individuals at risk for genetic prion disease.METHODS We recruited pre-symptomatic individuals with pathogenic mutations in the prion protein gene (PRNP; N=27) and matched controls (N=16), to donate cerebrospinal fluid (CSF) and blood at multiple timepoints to a cohort study at Massachusetts General Hospital. We quantified total prion protein (PrP) and real-time quaking-induced conversion (RT-QuIC) prion seeding activity in CSF, and the neuronal damage markers total tau (T-tau) and neurofilament light chain (NfL) in both CSF and plasma. We compared these markers cross-sectionally between mutation carriers and controls, evaluated short-term test-retest reliability over 2-4 months, and conducted a pilot longitudinal study over 10-20 months for a subset of participants.FINDINGS CSF PrP levels were stable on test-retest with a mean coefficient of variation of 7% both over 2-4 months in N=29 participants and over 10-20 months in N=10 participants. RT-QuIC was negative in 22/23 mutation carriers. The sole individual with positive RT-QuIC seeding activity at two study visits had steady CSF PrP levels and slightly increased tau and NfL concentrations compared with others, though still within the normal range, and remained asymptomatic one year later. Overall, tau and NfL showed no significant differences between mutation carriers and controls in either CSF or plasma.INTERPRETATION CSF PrP will be interpretable as a pharmacodynamic readout of the effects of a PrP-lowering therapeutic in pre-symptomatic individuals, and may serve as a surrogate biomarker in a “primary prevention” trial paradigm. In contrast, current markers of prion seeding activity and of neuronal damage do not reliably cross-sectionally distinguish mutation carriers from controls, arguing against the feasibility of a “secondary prevention” paradigm in which trials specifically recruit pre-symptomatic participants with prodromal evidence of pathology.Competing Interest StatementSEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; has received fees for consulting and/or advisory boards from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax and vTv; and has received grant support from Abbvie, Amylyx, EIP Pharma and Merck. SMV has received speaking fees from Illumina and has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals. EVM has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management and Guidepoint. KB holds the Torsten Söderberg Professorship, has served as a consultant or on advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ is a Wallenberg Academy Fellow, a cofounder of Brain Biomarker Solutions in Gothenburg A.B., a GU Ventures-based platform company at the University of Gothenburg, and has served on advisory boards for Roche Diagnostics, Wave, Samumed and CogRx.Clinical TrialN/A, this is not a clinical trial.Funding StatementThis study was supported by Prion Alliance, CJD Foundation (the Michael H. Cole, Cheryl Molloy, José A. Piriz and Sonia E. Piriz, Jeffrey A. Smith, and Mercies in Disguise Memorial Grants), the Broad Institute (Broad Next Gen Fund and direct donations to Prions@Broad), the National Science Foundation (GRFP 2015214731 to SMV), the National Institutes of Health (F31 AI122592 to EVM and R21 TR003040 to SEA), and an anonymous organization. We thank Brendan Blumenstiel and Anna Koutoulas for assistance with DNA sequencing. We are grateful to all of the volunteers who participated in this research study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesR source code for this study is available in a public repository: https://github.com/ericminikel/mgh_prnp_fluid_biomarkers De-identified data will be made available to qualified investigators upon request. https://github.com/ericminikel/mgh_prnp_fluid_biomarkers ER -